Home
James B. Lorens's picture

James B. Lorens

Professor
  • E-mailJim.Lorens@uib.no
  • Phone+47 55 58 67 76+47 975 57 112
  • Visitor Address
    Jonas Lies vei 91
  • Postal Address
    Postboks 7804
    5020 Bergen
Academic article
  • 2019. Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of SDHC. Cancer & Metabolism.
  • 2019. Adenoviral mediated mono delivery of BMP2 is superior to the combined delivery of BMP2 and VEGFA in bone regeneration in a critical-sized rat calvarial bone defect. Bone Reports.
  • 2019. AXL targeting reduces fibrosis development in experimental unilateral ureteral obstruction. Physiological Reports. 1-20.
  • 2019. AXL targeting overcomes human lung cancer cell resistance to NK- And CTL-mediated cytotoxicity. Cancer immunology research. 1789-1802.
  • 2019. A Functional Role of GAS6/TAM in Nonalcoholic Steatohepatitis Progression Implicates AXL as Therapeutic Target. Cellular and Molecular Gastroenterology and Hepatology (CMGH).
  • 2018. Microenvironment-Induced Non-sporadic Expression of the AXL and cKIT Receptors Are Related to Epithelial Plasticity and Drug Resistance. Frontiers in Cell and Developmental Biology.
  • 2018. Identifying Lysophosphatidic Acid Acyltransferase β (LPAAT‐β) as the Target of a Nanomolar Angiogenesis Inhibitor from a Phenotypic Screen Using the Polypharmacology Browser PPB2. ChemMedChem. 224-236.
  • 2018. High-Dimensional Phenotyping Identifies Age-Emergent Cells in Human Mammary Epithelia. Cell reports. 1205-1219.
  • 2018. A novel SRC-2-dependent regulation of epithelial-mesenchymal transition in breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology. 57-70.
  • 2017. Small-Molecule Inhibition of Axl Targets Tumor Immune Suppression and Enhances Chemotherapy in Pancreatic Cancer. Cancer Research. 246-255.
  • 2017. Microsphere cytometry to interrogate microenvironment-dependent cell signaling. Integrative Biology. 123-134.
  • 2017. Clear cell renal cell carcinoma is linked to epithelial-to-mesenchymal transition and to fibrosis. Physiological Reports. 1-18.
  • 2017. Association of Warfarin Use With Lower Overall Cancer Incidence Among Patients Older Than 50 Years. JAMA Internal Medicine. 1774-1780.
  • 2017. Acquisition of tumor cell phenotypic diversity along the EMT spectrum under hypoxic pressure: Consequences on susceptibility to cell-mediated cytotoxicity. Oncoimmunology. 1-11.
  • 2015. Warfarin blocks Gas6-mediated Axl activation required for pancreatic cancer epithelial plasticity and metastasis. Cancer Research. 3699-3705.
  • 2015. Vimentin-ERK signaling uncouples slug gene regulatory function. Cancer Research. 2349-2362.
  • 2015. The immortality two-step. Cell Cycle. 798 pages.
  • 2015. Cellular context-mediated Akt dynamics regulates MAP kinase signaling thresholds during angiogenesis. Molecular Biology of the Cell. 2698-2711.
  • 2015. A rapid in vivo screen for pancreatic ductal adenocarcinoma therapeutics. Disease Models and Mechanisms. 1201-1211.
  • 2015. A new live-cell reporter strategy to simultaneously monitor mitochondrial biogenesis and morphology. Scientific Reports.
  • 2014. Mesenchymal stem cells induce endothelial cell quiescence and promote capillary formation. Stem Cell Research & Therapy.
  • 2014. In Vitro Characterization of Valproic Acid, ATRA, and Cytarabine Used for Disease-Stabilization in Human Acute Myeloid Leukemia: Antiproliferative Effects of Drugs on Endothelial and Osteoblastic Cells and Altered Release of Angioregulatory Mediators by Endothelial Cells. Leukemia Research and Treatment.
  • 2014. Flow cytometry-based functional selection of RNA interference triggers for efficient epi-allelic analysis of therapeutic targets. BMC Biotechnology.
  • 2014. Effects of enoxaparin and dalteparin on proliferation and migration of patient-derived vascular smooth muscle cells . VASA. 124-131.
  • 2014. Automated quantification and integrative analysis of 2D and 3D mitochondrial shape and network properties. PLOS ONE.
  • 2014. Auswirkungen von enoxaparin und dalteparin auf die proliferation und migration humaner vaskulärer glatter muskelzellen aus einem patientenkollektiv. VASA. 124-131.
  • 2014. Akt1 activity regulates vessel maturation in a tissue engineering model of angiogenesis. Tissue Engineering. Part A. 2590-2603.
  • 2014. Age-Related Dysfunction in Mechanotransduction Impairs Differentiation of Human Mammary Epithelial Progenitors. Cell reports. 1926-1939.
  • 2013. p63 attenuates epithelial to mesenchymal potential in an experimental prostate cell model. PLOS ONE. 12 pages.
  • 2013. Nitroreductase, a near-infrared reporter platform for in vivo time-domain optical imaging of metastatic cancer. Cancer Research. 1276-1286.
  • 2013. Evaluating extracellular matrix influence on adherent cell signaling by cold trypsin phosphorylation-specific flow cytometry. BMC Cell Biology. 7 pages.
  • 2013. Endothelial microvascular networks affect gene-expression profiles and osteogenic potential of tissue-engineered constructs. Stem Cell Research & Therapy. 10 pages.
  • 2013. Domains I and IV of annexin A2 affect the formation and integrity of in vitro capillary-like networks. PLOS ONE. 12 pages.
  • 2013. Contextual compound screening for improved therapeutic discovery. ChemBioChem. 2512-2518.
  • 2013. Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma. Blood. 2443-2452.
  • 2012. Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia. Leukemia. 910-917.
  • 2012. Soluble mediators released by acute myeloid leukemia cells increase capillary-like networks. European Journal of Haematology. 478-490.
  • 2012. S100A14 inhibits proliferation of oral carcinoma derived cells through G1-arrest. Oral Oncology. 219-225.
  • 2012. Osteogenic stimulatory conditions enhance growth and maturation of endothelial cell microvascular networks in culture with mesenchymal stem cells. Journal of Tissue Engineering.
  • 2012. Ectopic expression of Flt3 kinase inhibits proliferation and promotes cell death in different human cancer cell lines. Cell Biology and Toxicology. 201-212.
  • 2012. Camptothecin-7-yl-methanthiole: semisynthesis and biological evaluation. ChemMedChem. 2134-2143.
  • 2012. A combined targeted/phenotypic approach for the identification of new antiangiogenics agents active on a zebrafish model: From in silico screening to cyclodextrin formulation. Bioorganic & Medicinal Chemistry Letters. 5579-5583.
  • 2011. Vimentin regulates EMT induction by Slug and oncogenic H-ras and migration by governing Axl expression in breast cancer. Oncogene. 1436-1448.
  • 2011. Isosteric replacement of the Z-enone with haloethyl ketone and E-enone in a resorcylic acid lactone series and biological evaluation. Bioorganic & Medicinal Chemistry Letters. 1167-1170.
  • 2011. Efficient in vivo vascularization of tissue-engineering scaffolds. Journal of Tissue Engineering and Regenerative Medicine. E52-E62.
  • 2011. A novel brain metastases model developed in immunodeficient rats closely mimics the growth of metastatic brain tumours in patients. Neuropathology and Applied Neurobiology. 189-205.
  • 2010. Synthesis and biological evaluation of new camptothecin derivatives obtained by modification of position 20. Bioorganic & Medicinal Chemistry. 8660-8668.
  • 2010. Isosteric replacement of the Z-enone with haloethyl ketone and E-enone in a resorcyclic acid lactone series and biological evaluation. Bioorganic & Medicinal Chemistry Letters. 1167-1170.
  • 2010. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proceedings of the National Academy of Sciences of the United States of America. 1124-1129.
  • 2010. A novel imaging-based high-throughput screening approach to anti-angiogenic drug discovery. Cytometry. 41-51.
  • 2009. Mural cell associated VEGF is required for organotypic vessel formation. PLOS ONE.
  • 2009. Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood. 3439-3447.
  • 2009. A novel imaging-based high-throughput screening approach to anti-angiogenic drug discovery. Cytometry Part A. 41-51.
  • 2008. Enhanced gene expression from retroviral vectors. BMC Biotechnology. 6 pages.
  • 2007. The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells. British Journal of Haematology. 814-828.
  • 2007. Target discovery using retroviruses. Expert Opinion on Drug Discovery. 1285-1300.
  • 2007. RACK1 regulates Ki-Ras-mediated signaling and morphological transformation of NIH 3T3 cells. International Journal of Cancer. 961-969.
  • 2007. In vivo optical Imaging of acute myeloid leukemia by green fluorescent protein: Time-domain autofluorescence decoupling, fluorophore quantification, and localization. Molecular Imaging. 193-204.
  • 2007. Expanding the spectrum of genetic elements transferable by retroviral vectors. DNA and Cell Biology. 773-779.
  • 2004. Stable, stoichiometric delivery of diverse protein functions. Journal of Biochemical and Biophysical Methods. 101-110.
  • 2004. Isolation of Genetic Effectors using the Tetracycline-Regulatable System. Genomu Igaku : Genome Medicine.
  • 1999. Salmon eggshell protein expression: A marker for environmental estrogens. Marine Biotechnology. 252-260.
  • 1999. Salmon Eggshell Protein Expression: A Marker for Environmental Estrogens. Marine Biotechnology. 252-260.
  • 1995. Embryonic expression and DNA-binding properties of zebrafish pax-6. Biochemical and Biophysical Research Communications - BBRC. 122-128.
  • 1993. Expression of growth hormone genes in Atlantic salmon. Journal of Molecular Endocrinology. 167-179.
  • 1993. Biotechnology in Aquaculture, with Special Reference to Transgenic Salmon. Biotechnology & Genetic Engineering Reviews. 31-56.
  • 1992. The complete nucleotide sequence of the Atlantic salmon growth hormone I gene. Biochimica et Biophysica Acta. 345-348.
Academic lecture
  • 2013. Prevascularization of tissue-engineered constructs with endothelial and mesenchymal stem cells.
Masters thesis
  • 2019. The Role of Axl in Cancer and Stem Cell Plasticity: in vivo Lineage Tracing and Imaging Mass Cytometry Analysis.
  • 2018. Investigating the role of vitamin K in Axl-mediated melanoma progression and chemotherapeutic resistance.
  • 2017. Axl Inhibition Enhances Sensitivity of BRAF Mutant Melanoma Cells to Vemurafenib.
  • 2015. The role of Axl in melanoma metastasis.
  • 2013. Metabolic reprogramming in Slug and Twist overexpressing MCF10A cells.
  • 2013. In vitro phenotypic patterning of vascular cells by nano- and micro-design of the matrix substatum.
  • 2012. A study of mitochondrial function, ROS and signaling in Twist overexpressing cells.
  • 2010. Effekten av arakidonsyremetabolitten prostaglandin E2 (PGE2) på humane endotelceller.
  • 2008. The disruption of VEGF signalling by the inhibition of delta 5- fatty acid desaturase (dFADS) in HUVECs.
  • 2008. Assessing Blood Vessel Formation and Maturation in Tissue Engineering Implants -The Role of Akt Kinase.
  • 2006. Knockdown of p110β subunit of phosphatidylinositol 3-kinase in human umbilical vein endothelial cells with small interfering RNA.
Letter to the editor
  • 2018. In reply. JAMA Internal Medicine. 585-586.
Doctoral dissertation
  • 2019. The role of AXL and the microenvironment in cancer cell plasticity and therapy responses. A study in non-small cell lung cancer models.
  • 2019. The receptor tyrosine kinase AXL in tumor phenotypic plasticity and acquired resistance to cancer targeted- and immunotherapy.
  • 2018. The effects of ageing on microenvironment-contextual epithelial cell signalling .
  • 2017. Mechanisms of AXL Mediated Cell Plasticity and Drug Resistance .
  • 2017. Investigations of the cancer therapeutic and protective effects of warfarin-mediated inhibition of the receptor tyrosine kinase AXL.
  • 2016. The Role of Age in Cellular Responses to Microenvironmental Cues as a Breast Cancer Susceptibility Factor.
  • 2015. The role of Axl signaling in phenotypic plasticity in normal and neoplastic epithelial cells.
  • 1993. Molecular studies on the gene structure and expression of Atlantic salmon growth hormone. (dr.scient).
Academic chapter/article/Conference paper
  • 2020. Autophagy mediated danger signaling regulates tumor immunosurveillance and may potentiate the effects of anti-cancer immunotherapy through increased adjuvanticity. 22 pages.
  • 2017. The Role of Axl Receptor Tyrosine Kinase in Tumor Cell Plasticity and Therapy Resistance. 28 pages.
  • 2013. The Tumor Microenvironment as a Transient Niche: A Modulator of Epigenetic States and Stem Cell Funct. 16 pages.
  • 2013. Image-based high-throughput screening for inhibitors of angiogenesis. 13 pages.
  • 2008. Comprehensive Analysis of Gene Function: RNA interference and Chemical Genomics. 13 pages.
  • 1993. Cloning and characterization of growth regulating genes from Atlantic salmon: A strategy for increasing growth rate by microinjection of a modified growth hormone gene into fertilized salmon eggs. 7 pages.
Abstract
  • 2018. Update on the randomised phase Ib/II study of the selective small molecule AXL inhibitor bemcentinib (BGB324) in combination with either dabrafenib/trametinib or pembrolizumab in patients with metastatic melanoma. Annals of Oncology. viii452-viii452.
  • 2013. Warfarin blocks Gas6-mediated Axl activation required for pancreatic tumor EMT and metastasis. Annals of Surgical Oncology. S133-S133.
  • 2013. Axl, a therapeutic target in AML mediates stroma-induced chemoresistance. Onkologie (Basel). 44-44.
  • 2011. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Clinical and Experimental Metastasis. 234-235.
  • 2009. The receptor tyrosine kinase Axl controls breast carcinoma cell invasiveness and tumor formation by regulating E-cadherin. Clinical and Experimental Metastasis. 863-863.
  • 2009. CARFILZOMIB: A SELECTIVE INHIBITOR OF THE CHYMOTRYPSIN-LIKE ACTIVITY OF THE CONSTITUTIVE PROTESOME AND IMMUNOPROTEASOME HAS ANTI-TUMOR ACTIVITY ON MULTIPLE MYELOMA, LYMPHOMA AND LEUKEMIA CELLS WITH MINIMAL EFFECTS ON NORMAL CELLS. Haematologica. 148-149.
  • 2008. The scaffold protein RACK1 regulates Ki-Ras-mediated signaling and morphological transformation of NIH 3T3 cells. The FEBS Journal. 315-315.
  • 2007. Anti-tumor activity of immunoproteasome selective inhibitors. Blood. 477A-478A.
Poster
  • 2013. Endothelial Microvascular Networks Influence Gene Expression Profiles in MSCs.
  • 2012. Osteogenic conditions stimulate microvascular networks – establishing culture conditions for stem cell based reconstruction of bone defects.
  • 2008. Co-culuture of endothelial cells and mesenchymal stem cells on 3D scaffolds.
  • 2007. Development of a near infrared reporter system for in vivo imaging.
  • 2007. Anti-Tumor Activity of Immunoproteasome Selective Inhibitors.
Errata
  • 2016. Corrigendum: A new live-cell reporter strategy to simultaneously monitor mitochondrial biogenesis and morphology. Scientific Reports.
Academic literature review
  • 2017. Adaptive mechanisms of resistance to anti-neoplastic agents. 53-66.
  • 2014. Molecular deconstruction, detection, and computational prediction of microenvironment-modulated cellular responses to cancer therapeutics. 123-131.
  • 2010. Image-based high-throughput screening for anti-angiogenic drug discovery. 3958-3963.
  • 2010. High content screening: seeing is believing. 237-245.
  • 2007. RNAi screening for therapeutic targets in human malignancies. 337-343.
  • 2007. MicroRNAs in tumorigenesis. 320-325.

More information in national current research information system (CRIStin)

A full bibliography is available here

Prof. Lorens completed undergraduate studies at Carleton College (USA) and University of Bergen (UiB), and graduate studies in chemistry (MS) and molecular biology (PhD) at UiB in 1993. He did postdoctoral work with Prof. Garry Nolan at Stanford University studying tumor and immune cell apoptosis mechanisms, before joining Rigel Pharmaceuticals in 1997. As one of the first scientists at Rigel, Prof. Lorens led technology development and was later Director of Oncology R&D. He returned to UiB as a Professor in the Medical Faculty, starting his academic laboratory in the Dept. Biomedicine in 2004 to focus on cancer research. Prof. Lorens is a principal investigator at the Center for Cancer Biomarkers, Norwegian Center of Excellence. He founded BerGenBio AS in 2008 to facilitate clinical translation of his group’s pioneering research on the Axl receptor tyrosine kinase. He continues to serve as Chief Scientific Officer. BerGenBio’s Axl inhibitor (BGB324) is currently in Phase I/II clinical trials to treat cancer.

In addition to his university research, teaching and supervisory activities, Prof. Lorens serves on the Editorial Board of Cancer Research and is an Affiliate at Lawrence Berkeley National Laboratory (USA). He has held several research administration and scientific advisory positions, including a current appointment to the board of the Research Council Division of Innovation. He has received several awards recognizing his achievements in innovation and holds several patents. A full bibliography is available here

Research groups